CLAIMS

1. A dosage form comprising (*S*)-bupropion which is at least 95% enantiomerically pure, wherein the (*S*)-bupropion is not deuterium-enriched.

2. The dosage form of claim 1, which contains 50 mg to 100 mg of (*S*)-bupropion.

3. The dosage form of claim 1, which contains 100 mg to 200 mg of (*S*)-bupropion.

4. The dosage form of claim 1, 2, or 3, wherein the dosage form contains less than 0.1% of any other active pharmaceutical agent.

5. The dosage form of claim 1, 2, 3, or 4, wherein the dosage form achieves a C_{max} of (*S*)-bupropion that is at least 60 ng/mL when administered to a human being in need thereof.

6. The dosage form of claim 1, 2, 3, 4, or 5, wherein the dosage form achieves a C_{max} of (*R,R*)-hydroxybupropion that is at least 500 ng/mL when administered to a human being in need thereof.

7. The dosage form of claim 1, 2, 3, 4, 5, or 6, wherein the dosage form achieves an $AUC_{0\text{-}12}$ of (*S*)-bupropion that is at least 400 ng·hr/mL when administered to a human being in need thereof.

8. The dosage form of claim 1, 2, 3, 4, 5, 6, or 7, wherein the dosage form achieves an $AUC_{0\text{-}12}$ of (*R,R*)-hydroxybupropion that is at least 7000 ng·hr/mL when administered to a human being in need thereof.

9. The dosage form of claim 1, 2, 3, 4, 5, 6, 7, or 8, wherein the dosage form provides sustained release of the (*S*)-bupropion.

10. The dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, or 9, wherein the dosage form is well tolerated when administered to a human being such that an adverse effect associated with administration of the dosage form is reduced, without loss of efficacy.

11. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 for the manufacture of a medicament for treating a condition that is treatable with racemic bupropion in a human being in need thereof, wherein the condition comprises a neurological disorder, a psychiatric disorder, a neuropsychiatric disorder, or a related condition.

12. The use of claim 11, wherein the human being having the condition that is treatable by orally administering a reference dosage form containing a first amount of racemic bupropion at a first dosing frequency; and

orally administering a dosage form containing a second amount of (*S*)-bupropion that is at least 95% enantiomerically pure at the first dosing frequency to achieve the same therapeutic effect that would be achieved by administering the reference dosage form at the first dosing frequency;

wherein the first dosing frequency is once daily or twice daily; and

wherein the second amount is about 40% to about 60% of the first amount.

13. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 for the manufacture of a medicament for treating a central nervous system (CNS) disorder.

14. The use of claim 13, wherein the CNS disorder comprises depression.

15. The use of claim 13, wherein the CNS disorder comprises treatment-resistant depression.

16. The use of claim 13, wherein the CNS disorder comprises an addictive disorder.

17. The use of claim 13, wherein the CNS disorder comprises a nicotine addiction.

18. The use of claim 13, wherein the CNS disorder comprises an alcohol addiction.

19. The use of claim 13, wherein the CNS disorder comprises attention deficit/hyperactivity disorder.

20. Use of the dosage form of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 for the manufacture of a medicament for relieving pain in a human being in need thereof.

21. The dosage form of claim 1, wherein the dosage form is formulated for administration once daily or twice daily.